Effects of bivalirudin on instant blood-mediated inflammatory reaction after intraportal islet transplantation
Cell Transplantation · 2025
DOI: 10.1177/09636897251385284 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Transplantation, 2025. Verfasst von Mei Liang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Guangxi University of Chinese Medicine, Nanning, China. Hauptthemen laut MEDLINE: Hirudins, Islets of Langerhans Transplantation, Peptide Fragments, Inflammation. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guangxi Key Research and Development Program, Guangxi Center for Clinical Medical Research on Integrated Traditional Chinese and Western Medicine for Kidney Diseases, Guangxi Graduate Education Innovation Project.
Abstract (Originalsprache)
The instant blood-mediated inflammatory reaction (IBMIR) is a major barrier to successful intraportal islet engraftment. Bivalirudin, a direct thrombin inhibitor, could mitigate IBMIR by suppressing thrombin activity and platelet activation, yet its role in islet transplantation remains insufficiently defined. Using a portal vein islet transplantation model with rat islets, we compared bivalirudin treatment (BT) with heparin treatment (HT). In recipient Wistar rats, both BT and HT increased circulating antithrombin and prolonged activated partial thromboplastin time (APTT) versus saline. BT more effectively reduced serum β-thromboglobulin (β-TG) and thrombin–antithrombin (TAT) complexes, and it decreased peri-graft fibrin deposition to a greater extent than HT. BT and HT also attenuated hepatic NF-κB activation, lowered serum TNF-α, and diminished inflammatory-cell infiltration within grafts, with more pronounced effects under BT. In BALB/c-nu recipient mice, BT and HT similarly reduced graft inflammatory infiltration. Functionally, a higher proportion of diabetic recipients achieved normoglycemia after BT or HT than after saline, and BT yielded a greater normoglycemia rate with a shorter time-to-normoglycemia than HT. Collectively, BT and HT alleviate coagulation activation and inflammatory infiltration characteristic of IBMIR, thereby improving post-transplant islet survival. BT demonstrated greater anti-thrombotic and anti-inflammatory activity than HT in this setting, supporting bivalirudin as a promising adjunct anticoagulant strategy for intraportal islet transplantation and potentially other cell-therapy applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School, Guangxi University of Chinese Medicine, Nanning, China.
- Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, China.
- Guangxi Clinical Research Center for Kidney Diseases of Integrated Traditional Chinese and Western Medicine, Nanning, China.
ORCID-Profile: Mei Liang
Förderung
- Guangxi Key Research and Development Program
- Guangxi Center for Clinical Medical Research on Integrated Traditional Chinese and Western Medicine for Kidney Diseases
- Guangxi Graduate Education Innovation Project
Zitieren
APA
Liang, M., Wu, P., Zhao, Z., Li, Y., Ye, X., Cui, C., Chen, S., Yang, Y., & Gao, H. (2025). Effects of bivalirudin on instant blood-mediated inflammatory reaction after intraportal islet transplantation. Cell Transplantation. https://doi.org/10.1177/09636897251385284
Vancouver
Liang M, Wu P, Zhao Z, Li Y, Ye X, Cui C, et al. Effects of bivalirudin on instant blood-mediated inflammatory reaction after intraportal islet transplantation. Cell Transplantation. 2025. doi:10.1177/09636897251385284
BibTeX
@article{Liang2025,
author = {Liang, Mei and Wu, Peizhong and Zhao, Ziyuan and Li, Yiwen and Ye, Xuejing and Cui, Chang and Chen, Sheng and Yang, Yuwei and Gao, Hongjun},
title = {Effects of bivalirudin on instant blood-mediated inflammatory reaction after intraportal islet transplantation},
journal = {Cell Transplantation},
year = {2025},
doi = {10.1177/09636897251385284}
}
EUVIMED